Anticonvulsant Hydantoin and CBD Composition for Seizure Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for seizure disorders and epilepsy often have limited efficacy and are associated with significant side effects, as they fail to adequately modulate key receptors and can cause metabolic degradation of anticonvulsant drugs, leading to reduced bioavailability and increased side effects.
Innovation Solution
A composition combining an anticonvulsant hydantoin drug, phytocannabinoid cannabidiol (CBD), and a fat-soluble vitamin like vitamin A, with the option of a water-soluble vitamin like folic acid, to enhance bioavailability and reduce side effects by inhibiting metabolic degradation and increasing the cumulative anticonvulsant effect.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard anti-epileptic drugs are used alone, then treatment simplicity is maintained, but efficacy is limited and side effects increase
Solution Approach 1:
The patent combines three substances with different mechanisms of action: CBD (acting on GABA and other receptors), hydantoin (acting on sodium channels), and P450 blocker (inhibiting metabolic degradation). This multi-component combination addresses multiple seizure pathways simultaneously while the P450 blocker prevents metabolic interference, thereby improving efficacy and reducing side effects compared to monotherapy
Solution Approach 2:
The invention creates a composite pharmaceutical formulation integrating three distinct therapeutic agents. Each component contributes unique pharmacological properties: CBD provides broad-spectrum anticonvulsant activity, hydantoin offers sodium channel stabilization, and the P450 blocker ensures sustained drug levels. The composite formulation synergistically enhances therapeutic effect while minimizing adverse reactions
2Reliability
If CBD dosage is increased to improve seizure control, then anticonvulsant effect increases, but metabolic degradation increases and bioavailability decreases
Solution Approach 1:
The P450 blocking compound acts as an intermediary that protects CBD from metabolic degradation by cytochrome P450 enzymes. By inhibiting the enzymatic pathway responsible for CBD breakdown, the mediator substance maintains higher circulating levels of CBD, thereby improving bioavailability and reducing the required dosage for effective seizure control
3Device complexity
If monotherapy is used, then treatment complexity is minimized, but efficacy is achieved in only up to 25 percent of patients
Solution Approach 1:
The patent merges three therapeutic agents into a single comprehensive treatment regimen that addresses multiple seizure mechanisms. The combination of CBD, hydantoin, and P450 blocker provides broader spectral coverage than monotherapy, achieving efficacy in patients who would otherwise respond poorly to single-agent treatment, while maintaining manageable treatment complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination effectively reduces seizure frequency and intensity, decreases undesirable side effects such as skin rashes, and stabilizes sodium channels, providing a more effective treatment for epilepsy with reduced drug dosages and improved bioavailability of CBD.
Implementation Method 1
a P450 blocking compound such as vitamins A, D, E and K
Implementation Method 2
Epilepsy is due to multiple factors including Sodium, Potassium, GABA and NMDA. Modulating one or more of these receptors are required to maximally control epilepsy
Data Source
AI summary
A composition for treating seizure disorders such as epilepsy comprises (i) an anticonvulsant drug of the hydantoin family; (ii) phytocannabinoid cannabidiol (CBD); and (iii) a fat-soluble vitamin.